ArticleJournal of molecular neuroscience : MN2000
VIP-Related protection against lodoacetate toxicity in pheochromocytoma (PC12) cells: a model for ischemic/hypoxic injury.
Article in Journal of molecular neuroscience : MN, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Using Plants as a Source of Potential Therapeutics for the Treatment of Alzheimer's Disease.The Yale journal of biology and medicine · 2020Article
- ADNP differentially interact with genes/proteins in correlation with aging: a novel marker for muscle aging.GeroScience · 2019Article
- Autophagy has a key role in the pathophysiology of schizophrenia.Molecular psychiatry · 2015Article
- Article
- Back to the future with phenotypic screening.ACS chemical neuroscience · 2014Review
- Involvement of PACAP/ADNP signaling in the resistance to cell death in malignant peripheral nerve sheath tumor (MPNST) cells.Journal of molecular neuroscience : MN · 2012Article
- Chemical modification of the multitarget neuroprotective compound fisetin.Journal of medicinal chemistry · 2012Article
- Neuropeptide GPCRs in neuroendocrinology: the case of activity-dependent neuroprotective protein (ADNP).Frontiers in endocrinology · 2012Article
- Article
- Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.ASN neuro · 2011Review
- Delayed treatment with a novel neurotrophic compound reduces behavioral deficits in rabbit ischemic stroke.Journal of neurochemistry · 2011Article
- Neuroprotective protein and carboxypeptidase E.Journal of molecular neuroscience : MN · 2009Review
- VIP, from gene to behavior and back: summarizing my 25 years of research.Journal of molecular neuroscience : MN · 2008Article
- ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance.Journal of molecular neuroscience : MN · 2008Article
- A novel approach to screening for new neuroprotective compounds for the treatment of stroke.Brain research · 2007Article
- Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry.Journal of molecular neuroscience : MN · 2007Article
- Vasoactive intestinal peptide (VIP) regulates activity-dependent neuroprotective protein (ADNP) expression in vivo.Journal of molecular neuroscience : MN · 2007Article
- Neuroprotection of cerebrolysin in tissue culture models of brain ischemia: post lesion application indicates a wide therapeutic window.Journal of neural transmission (Vienna, Austria : 1996) · 2006Article
- Neonatal mice of the Down syndrome model, Ts65Dn, exhibit upregulated VIP measures and reduced responsiveness of cortical astrocytes to VIP stimulation.Journal of molecular neuroscience : MN · 2006Article
- N-PEP-12--a novel peptide compound that protects cortical neurons in culture against different age and disease associated lesions.Journal of neural transmission (Vienna, Austria : 1996) · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the protective properties of peptides related functionally and/or structurally to vasoactive intestinal peptide (VIP), PC12 cultures were treated with iodoacetate as a model for neuronal ischemic/hypoxic injury. Brain tissue can be pre-conditioned against lethal ischemia by several mechanisms including sub-lethal ischemia, moderate hypoglycemia, heat shock, and growth factors. In the present study, a superactive VIP lipophilic analog (Stearyl-Norleucine17-VIP; SNV) was used to pre-condition media of PC12 cells. After removal of the conditioned media, the cultures were exposed to iodoaceate, which inhibits glycolysis. Protective efficacy against iodoacetate-induced injury was assessed by the measurements of lactate dehydrogenase (LDH) activity in the media. Treatment with iodoacetate for 2.5 h produced a twofold increase in LDH activity in the media. The protective effect of SNV had an EC50 of 1 pM. Comparison of the preconditioning time required for full protection by SNV showed no apparent difference between a 15 min and a 2 h incubation period prior to the addition of iodoacetate. Iodoacetate treatment produced a 20% decrease in the RNA transcripts encoding activity-dependent neuroprotective protein (ADNP), a novel glia-derived protein that is regulated by VIP. The iodoacetate-associated reduction in ADNP mRNA was prevented by pre-treatment with SNV. These effects imply that SNV provides a regulatory mechanism for ADNP synthesis during glycolytic stress. Furthermore, a short exposure to SNV provided potent protection from iodoacetate-induced toxicity suggesting that SNV may have therapeutic value in the treatment of ischemic/hypoxic injury.
Indexed as
Identifiers
11303779What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.